Our industry-recognized Education team is committed to sharing program findings, best practices, insights, and trends from our educational programs across a range of therapeutic areas. These findings are regularly published in peer-reviewed journals, as well as presented at medical, patient, and industry conferences.
[vc_row][vc_column][vc_column_text]Medlive, a company focused on empowering clinicians, patients, and caregivers through digital education, is proud to announce that two abstracts have been accepted for presentation at the 66th ASH® Annual Meeting and Exposition taking place December 7 – 10, 2024 in San Diego. Details for the abstract presentations are as...
The treatment of Rett Syndrome (RTT), a rare, genetic neurological disorder affecting young children that leads to severe impairments, is continuing to evolve. The first therapy was approved in March 2023, and with several investigational assets on the horizon, there is a critical need to educate both community-based clinicians and...
*This information was originally published as part of an abstract for ACAAI’s 2024 Annual Scientific Meeting* Understanding Asthma and the Role of Biologics Asthma, a serious chronic lung disease, affects 26.8 million adults and 4.5 million children in the U.S. according to the American Lung Association. Research on the pathophysiology...
Triple-negative breast cancer (TNBC) remains difficult to treat, and disproportionately affects women of color. To address these challenges, PlatformQ Health joined together with TOUCH: The Black Breast Cancer Alliance and the National Breast Cancer Foundation to develop a tethered educational program to empower patients in treatment decision making and to help...
Early treatment of homozygous familial hypercholesterolemia (HoFH) improves outcomes for children and reduces the risk of progressive atherosclerotic cardiovascular disease. Unfortunately, the disease often goes undetected until it is in the advanced stages. To address this issue, PlatformQ Health and the American Society for Preventive Cardiology teamed up to develop...
For people with moderate-to-severe asthma, personalization of biologic agents is warranted based on factors such as biomarkers and comorbidities. PlatformQ Health and the Asthma and Allergy Foundation of America (AAFA) conducted a CME-certified, case based, expert panel discussion that featured a live Q&A session with leading faculty from the Asthma...
PlatformQ Health is known for its outcomes-driven education. At this year’s European Conference on Rare Diseases, we co-presented two posters highlighting outcomes and lessons learned from recent programming. Rare disease education People with rare diseases often wait years for a correct diagnosis. Ongoing education of clinicians and the general public...
Using Gene Therapy to Treat Duchenne Muscular Dystrophy The first FDA-approved gene therapy for pediatric patients with Duchenne muscular dystrophy (DMD) is now available. This is a genetic disorder that presents as progressive muscle degeneration and weakness. A live CME activity was held to educate clinicians about this newly available...
Clinical trials are crucial for advancing care for non-Hodgkin's lymphoma (NHL), however, accrual in these studies remains low. To address this issue, PlatformQ Health, the Leukemia & Lymphoma Society, BlackDoctor.org, and Partners for Advancing Clinical Education co-produced the BUILD-NHL Trial Equity Initiative. The goal was to reduce disparities in trial...
PlatformQ Health, the Asthma and Allergy Foundation of America (AAFA), and BlackDoctor.org were seeking to understand whether aligned (sequential patient/provider) education could help improve health equity for those suffering from conditions such as asthma and atopic dermatitis. Black people with asthma are more likely to succumb to asthma than White...
[vc_row][vc_column][vc_column_text]Immunotherapy is increasingly being used to treat patients with melanoma and other types of cancer. Management of these therapies differs distinctly from previous standard-of-care options such as chemotherapy. Optimizing care involves educating a multidisciplinary healthcare team about therapy management as well as educating patients about therapies and the factors that...
[vc_row][vc_column][vc_column_text]In the wake of FDA approvals for treating myasthenia gravis (gMG, healthcare providers have the ability to individualize treatment. As these new therapies become adopted, it's crucial to educate patients and providers about issues such as disease presentation, comorbidities, and patient preferences that may impact treatment decisions. To support patients...